Amplify Weight Loss Drug & Treatment ETF (THNR) Dividend Yield, History & Forecast

Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. It pays a current dividend yield of 1.67% ($0.41 per share annually (TTM)). The most recent ex-dividend date was December 30, 2025, with payment scheduled for December 31, 2025. market capitalization is approximately $6M. Review THNR dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

THNR fund composition

THNR holds 20 positions, with 66.0% of assets in its ten largest. It charges an expense ratio of 0.59%, and manages $5.7M.

Top 10 holdings

HoldingWeight
LLYEli Lilly & Co11.45%
NVONovo Nordisk A/S8.82%
AMGNAmgen Inc6.14%
ROP.SWRoche Holding AG5.87%
PFEPfizer Inc5.78%
ABBVAbbVie Inc5.71%
AZNAstraZeneca PLC5.68%
SRRKScholar Rock Holding Corp5.56%
GILDGilead Sciences Inc5.54%
REGNRegeneron Pharmaceuticals Inc5.42%

Sector allocation

Healthcare99.5%Financial Services0.3%Cash & Others0.2%

Frequently Asked Questions about Amplify Weight Loss Drug & Treatment ETF (THNR)

What is Amplify Weight Loss Drug & Treatment ETF's dividend yield?
Amplify Weight Loss Drug & Treatment ETF (THNR) pays a current trailing twelve-month dividend yield of 1.67%, which works out to $0.41 per share annually based on the most recent payout schedule.
When does Amplify Weight Loss Drug & Treatment ETF pay distributions?
The most recent ex-dividend date was December 30, 2025. The next scheduled dividend payment date is December 31, 2025.
What does Amplify Weight Loss Drug & Treatment ETF invest in?
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.